Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
192
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia

Colin D. Godwina Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;b Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USACorrespondence[email protected]
View further author information
,
Olivia M. Batesa Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Sae Rin Jeanc Eutropics Pharmaceuticals, Inc, Cambridge, MA, USAView further author information
,
George S. Laszloa Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Eliotte E. Garlinga Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Mary E. Beddoea Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAView further author information
,
Michael H. Cardonec Eutropics Pharmaceuticals, Inc, Cambridge, MA, USAView further author information
&
Roland B. Waltera Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;b Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;d Department of Pathology, University of Washington, Seattle, WA, USA;e Department of Epidemiology, University of Washington, Seattle, WA, USAView further author information
 show all
Pages 2990-2994 | Received 19 Dec 2019, Accepted 14 Jun 2020, Published online: 04 Jul 2020

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
  • Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31(9):1855–1868.
  • Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019;3(1):96–104.
  • Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev. 2018;32(1):8–28.
  • Mei M, Aldoss I, Marcucci G, et al. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol. 2019;94(3):358–362.
  • Walter RB, Raden BW, Cronk MR, et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood. 2004;103(11):4276–4284.
  • Cianfriglia M, Mallano A, Ascione A, et al. Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line. Int J Oncol. 2010;36(6):1513–1520.
  • Laszlo GS, Harrington KH, Gudgeon CJ, et al. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget. 2016;7(28):43281–43294.
  • Laszlo GS, Beddoe ME, Godwin CD, et al. Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330. Haematologica. 2019;104(2):e59–e62. Feb
  • Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351–365.
  • Foight GW, Ryan JA, Gullá SV, et al. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 2014;9(9):1962–1968.
  • Pierceall WE, Kornblau SM, Carlson NE, et al. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther. 2013;12(12):2940–2949.
  • Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
  • Moujalled DM, Pomilio G, Ghiurau C, et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia. 2019;33(4):905–917.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.